Abstract: The present invention relates, in general, to a method of preventing or treating human immunodeficiency virus (HIV) infection, and in particular, to a method of preventing or treating HIV infection using a cobalamin. The invention further relates to compositions suitable for use in such a method.

Abstract: Fungicidal mixtures comprising as active components a) an amide compound of the formula I A—CO—NR1R2  I  in which A is an aryl group or an aromatic or non-aromatic, 5- or 6-membered heterocycle which has from 1 to 3 hetero atoms selected from O, N and S; where the aryl group or the heterocycle may or may not have 1, 2 or 3 substituents which are selected, independently of one another, from alkyl, halogen, CHF2, CF3, alkoxy, haloalkoxy, alkylthio, alkylsulfynyl and alkylsulfonyl; R1 is a hydrogen atom; R2 is a phenyl or cycloalkyl group which may or may not have 1, 2 or 3 substituents which are selected, independently of one another, from alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkyloxy, cyclo-alkenyloxy, phenyl and halogen, where the aliphatic and cycloaliphatic radicals may be partially or fully halogenated and/or the cycloaliphatic radicals may be substituted by from 1 to 3 alkyl groups and where the phenyl group may have from

Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: A pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater.

Abstract: Drug or foods and drink for prevention or treatment of diseases caused by abnormalities in cartilage tissues in which said drugs or foods and drinks have omega-9 unsaturated fatty acid as an active ingredient.

Abstract: It comprises a compound having antifungal activity as active principle, an inert core and a coating including said active principle, and is characterized in that said inert core has a particle size comprised between 50 and 600 &mgr;m, and in that said coating comprises a single layer obtained by spraying, on said inert core, a solution comprising a compound having antifungal activity, a hydrophilic polymer and a non-ionic surfactant. The method consists in carrying out a coating, comprising a single layer, of the inert cores having a size between 50 and 600 &mgr;m, by means of the spraying of a solution composed by the antifungal agent, the hydrophilic polymer and the non-ionic surfactant, at a constant coating speed throughout the whole process; and a single drying step of said coating in the same apparatus.

Abstract: Chemical compositions are provided, for use as topical anesthetics or skin refrigerants. These compositions do not cause the depletion of the stratospheric ozone layer and are non-toxic, non-carcinogenic and less flammable than ethyl chloride. Also these chemical compositions match the skin temperature versus time profile needed in the management of myofascial pain syndromes, for effectively freezing skin prior to minor skin surgery and for effectively freezing skin prior to giving painless injections.

Abstract: Controlled release of hydrophobic bioactive substances in vivo over an extended time period and without “bursts” of drug release is achieved using a liquid polymeric composition including a polymer such as poly(lactide-co-glycolide) copolymer in a mixture of hydrophilic and lipophilic solvents.

Abstract: Pharmaceutical formulations containing HIV protease inhibitors, specifically including 3S-[3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (alternatively known as VX 478 or 141W94), and a tocopherol, and their use in medical therapy are described.

Abstract: The present invention provides a method of making particles useful in drug delivery, comprising the steps of: contacting polyanionic polymers with cations in a stirred reactor so that polyanions and the cations react to form particles.

Abstract: A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.

Abstract: This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods of perivascular antiproliferative drug administration also are disclosed.

Abstract: The present invention provides methods for administering a taxane composition for the treatment of cancer. In one aspect, the compositions are not diluted prior to administration. Some embodiments provide methods for administering a taxane as a bolus injection or an intravenous infusion in less than about 30 minutes. In other aspects, the invention provides methods for administering a taxane to provide high concentrations of the taxane in blood or in tumors. Another aspect provides methods for administering a taxane to provide anti-tumor activities against solid tumors. In some embodiments, the methods provide anti-tumor activities against tumors that were resistant to conventional taxane administration methods. In some embodiments, the methods provide anti-tumor activities against colorectal tumors.

Abstract: Methods for performing a capsulorhexis are disclosed wherein a dye is used to stain a lens capsule of an eye. The dye is capable of staining tissue without diffusing through the tissue. Compositions including dyes that are useful in the methods are also disclosed.

Abstract: The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled compositions to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

Abstract: The invention relates to a method for finding nucleotide synthesis inhibitors which have a better therapeutic window. An efficacious dose of a nucleotide synthesis inhibitor is administered to a mammal. The concentration of the nucleotide synthesis inhibitor in the blood of the mammal is observed and it is determined whether the nucleotide synthesis inhibitor has a half-life which is shorter than that of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. The invention also relates to a method of using nucleotide synthesis inhibitors in the treatment of immunological diseases.

Abstract: The invention provides a material for use in a wound dressing or wound implant, the material comprising a plurality of beads, wherein each bead comprises a porous core of a first bioabsorbable material and a substantially non-porous layer of a second bioabsorbable material around the core. The porous core is preferably a sponge formed by freeze-drying a liquid suspension of the first bioabsorbable material. The preferred diameter of the beads is 0.1-4.0 mm, and the beads are preferably dispersed in a liquid or solid matrix. The invention also provides a method of making beads for use in the materials of the invention.

Abstract: Use of a tablet diet supplement for administration to a dialysis patient comprising a mixture of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine and L-valine, for preventing and/or correcting hypoalbuminemia in a patient on dialysis.

Abstract: A thickener composition containing a reaction product of a hydroxycarboxylic acid selected from the group consisting of tartaric acid, malic acid, citric acid and mixtures thereof, and a fatty alcohol polyglycol ether corresponding to formula I: R1O(CH2CH2O)nH  (I) wherein R1 is an alkyl and/or alkenyl group containing from 6 to 22 carbon atoms, and n is a number from 20 to 150.

Abstract: Method for preventing or inhibiting the transmission of HIV to susceptible uninfected cells by administering to the HIV, to cells infected with HIV, and/or to the uninfected cells, an effective amount of a compound of formula (I), wherein X is O or S, prior to the HIV or the cells infected with HIV, contacting the uninfected cells.